A Randomized Phase 2 Study of Peri-Operative Ipilimumab, Nivolumab and Cryoablation Versus Standard Peri-Operative Care in Women With Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- 22 Jul 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jul 2018 to 1 Dec 2019.
- 11 Feb 2019 Status changed from not yet recruiting to recruiting.
- 08 Jun 2018 New trial record